findmyKOL

Rajan Saggar, MD

Enriched profile

HS Clinical Professor of Medicine · University of California, Los Angeles

ORCIDNPI
Region🇺🇸 Los Angeles, CA · West · United StatesSpecialtyPulmonary DiseaseFocusPulmonary Hypertension Research and Treatments+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Rajan Saggar is HS Clinical Professor of Medicine at University of California, Los Angeles. OpenAlex indexes 271 publications with 8,466 citations (h-index 54); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Rajan Saggar, MD, is HS Clinical Professor of Medicine at University of California, Los Angeles (David Geffen School of Medicine). The public record shows 271 publications with 8,466 citations (h-index 54), centered on Pulmonary Hypertension Research and Treatments, Transplantation: Methods and Outcomes, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 15 companies.

  • Most recent indexed publication: 2024 · American journal of respiratory and critical care medicine
  • Top research focus: Pulmonary Hypertension Research and Treatments
  • 9 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 15 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Pulmonary Hypertension7 trialsHypertension7 trialsPulmonary Arterial Hypertension5 trialsIdiopathic Pulmonary Fibrosis4 trialsLung Diseases, Interstitial2 trialsPulmonary Embolism1 trialEmbolism1 trial

Research focus

OpenAlex concept fingerprint
Pulmonary Hypertension Research and TreatmentsTransplantation: Methods and OutcomesInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related DiseasesMedical Imaging and Pathology Studies

Drugs & molecules

across trials, industry payments and publications
Tyvasogeneric · TreprostinilClinical trialsIndustry payments276PublicationsUptravigeneric · SelexipagClinical trialsIndustry payments160PublicationsOpsumitgeneric · MacitentanClinical trialsIndustry payments135Publications

Works with

trial sponsors and companies reporting payments
United Therapeutics CorporationClinical trialsIndustry payments324Actelion Pharmaceuticals US, Inc.Clinical trialsIndustry payments183Merck Sharp & Dohme LLCClinical trialsIndustry payments100

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
271publications

Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.

8,466citations

Total citations across indexed works.

54h-index

Hirsch index (OpenAlex). i10-index 112.

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials
15companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    33.6%
    Endothelin Receptor Antagonist22.5%
    Opsumit60%Ambrisentan22%Letairis19%
    Part D<11 patients
    Soluble Guanylate Cyclase Stimulator2.6%
    Adempas100%
    Part D<11 patients
  • Anti-infectives

    18.2%
    Short-acting sulfonamides7.1%
    Sulfamethoxazole-Trimethoprim100%
    Part D36 patients
    Azole Antifungal3.4%
    Posaconazole100%
    Part D11 patients
  • Genitourinary & hormones

    15.3%
    Phosphodiesterase 5 Inhibitor15.3%
    Tadalafil80%Adcirca11%Sildenafil Citrate10%
    Part D<11 patients
5 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)94.7% facility · 5.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

1 congress contribution (2007) across ASCO per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

John A. Belperio85David J. Ross82Joseph P. Lynch74

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/rajan-saggar-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/rajan-saggar-31964a6

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/scientific-contributions/Rajan-Saggar-2154511451

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    phaware.medium.com/im-aware-that-i-m-rare-rajan-saggar-md-463-73e51fd8714e

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.medium.com
  • Other

    phaware.medium.com/im-aware-that-i-m-rare-rajan-saggar-md-515-a4deecd6a868

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.medium.com
  • X / Twitter

    x.com/phaware/status/1777359955768840350

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Fellowship

    Pulmonary & Critical Care Medicine, UCLA David Geffen School of Medicine

    2007
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org
  • Board Certified

    Pulmonary Disease, American Board of Internal Medicine

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org
  • Residency

    Internal Medicine, Medical College of Wisconsin Affiliated Hospitals

    2002
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org
  • MD

    Medical College of Wisconsin

    1999
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org

Editorial & leadership roles

journal and society appointments
  • Physician

    Pulmonology and Critical Care Medicine, UCLA Health (Ronald Reagan UCLA Medical Center and UCLA Santa Monica Medical Center)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org
  • Member

    Pulmonary Arterial Hypertension (PAH) Team, Pulmonary Vascular Disease Program, UCLA Health

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uclahealth.org

Media & interviews

press, podcasts and appearances
  • Podcast guest

    "I'm Aware That I'm Rare: the phaware podcast," interview 515, part of special PH-ILD treatment/innovation series

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.wordpress.com
  • Video speaker

    "Pulmonary Hypertension in ACHD," 2017 UCLA ACHD Symposium (YouTube)

    2017
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com
  • Podcast guest

    "I'm Aware That I'm Rare: the phaware podcast," interview 463 (pulmonary hypertension complications in lung disease)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phawarepodcast.libsyn.com

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.